| Name | Title | Contact Details |
|---|
Semper Laser is a laser hair removal company that specializes in providing affordable and advanced laser hair removal treatments for both men and women.
Genesis HealthCare System was created in 1997 as an affiliation between Bethesda Care System and Good Samaritan Medical Center — two health care organizations that had served the community for more than 100 years each. We are a not-for-profit organization that operates two hospital sites — Genesis-Bethesda and Genesis-Good Samaritan — in Zanesville, Ohio, and several affiliated health care organizations. By combining the resources of the two organizations, we have been able to provide several new services for the community, including open-heart surgery, a Level II neonatal intermediate care unit and enhanced cancer services. Our primary service area is a six-county region of southeastern Ohio, including Muskingum, Morgan, Perry, Coshocton, Noble and Guernsey counties.
ClearMedical Inc. is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Equipping Youth is a Cedar Rapids, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.